Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01144247 · ClinicalTrials.gov registry record · Phase 1
Cellular Immunotherapy Study for Brain Cancer
A Phase 1 study of Glioblastoma Multiforme and Anaplastic Astrocytoma, sponsored by Jonsson Comprehensive Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 10
- Enrollment target
- 1
- Study location
NCT01144247 is a Phase 1 study of Glioblastoma Multiforme and Anaplastic Astrocytoma that has completed, run by Jonsson Comprehensive Cancer Center. The registered enrollment target is 10 participants, below the 97-participant average among 88 other Glioblastoma Multiforme trials with a reported enrollment target (90% lower). The trial reports 1 study location across 1 state.
The verdict
NCT01144247, a Phase 1 study of Glioblastoma Multiforme and Anaplastic Astrocytoma, has completed, sponsored by Jonsson Comprehensive Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 10 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this research study to determine if treating recurrent malignant gliomas with another person's (donor) immune system cells known as aCTL cells, will be safe. This study will also try to determine if persons who receive aCTL's are more or less likely to survive their brain tumor than persons who had similar tumors in the past. Approximately 15 patients will be enrolled at UCLA.
Conditions Studied
Interventions
- DRUG alloreactive CTL
Study Locations (1)
California
- University of California, Los Angeles - Los Angeles
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2010-07 |
| Est. Completion | 2015-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01144247
The ClinicalTrials.gov registry entry for NCT01144247 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 97-participant average among 88 other Glioblastoma Multiforme trials with a reported enrollment target (90% lower). The listed sponsor is Jonsson Comprehensive Cancer Center, which has 321 total studies on file at ClinicalTrials.gov.
The record links to 6 conditions, with Glioblastoma Multiforme appearing as the primary indexed condition, and to 1 intervention - of which alloreactive CTL is the first listed.
NCT01144247 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT01144247 about?
NCT01144247 is a clinical study titled "Cellular Immunotherapy Study for Brain Cancer". The purpose of this research study to determine if treating recurrent malignant gliomas with another person's (donor) immune system cells known as aCTL cells, will be safe. This study will also try to determine if persons who receive aCTL's are more or less likely to survive their brain tumor than p...
What is the current status of trial NCT01144247?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 10 participants. The study started on 2010-07. Estimated completion is 2015-07.
What conditions does trial NCT01144247 study?
This clinical trial studies the following conditions: Glioblastoma Multiforme, Anaplastic Astrocytoma, Anaplastic Oligodendroglioma, Gliomas, Anaplastic Mixed Glioma.
What interventions are being tested in trial NCT01144247?
The interventions under investigation include: alloreactive CTL (DRUG).
Who is sponsoring clinical trial NCT01144247?
This trial is sponsored by Jonsson Comprehensive Cancer Center, which has 321 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01144247 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Glioblastoma Multiforme
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Trial of Anti-PD-1 Immunotherapy and Stereotactic Radiation in Patients With Recurrent Glioblastoma
RECRUITING · Phase 1
-
Study to Evaluate Safety, Tolerability, and Optimal Dose of Candidate GBM Vaccine VBI-1901 in Recurrent GBM Subjects
RECRUITING · Phase 1
-
Treatment of Relapsed/Refractory Intracranial Glioma in Patients Under 22 Years of Age
RECRUITING · Phase 1
-
Adenovirus Mediated Suicide Gene Therapy With Radiotherapy in Progressive Astrocytoma.
RECRUITING · Phase 1
-
HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors
RECRUITING · Phase 1
-
Autologous CAR-T Cells Targeting B7-H3 in Recurrent or Refractory GBM CAR.B7-H3Tc
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.